Evaluation of bacterial contamination and medium-term oncological outcomes of intracorporeal anastomosis for colon cancer: A propensity score matching analysis

Table 1 Patients’ characteristics before and after propensity score matching, n (%)

	Before propensity score matching			After propensity score matching
	IA (n = 52)	EA (n = 75)	P value	IA (n = 42)	EA (n = 42)	P value
Age (yr)	69 (38-91)	73 (38-92)	0.1289	72 (38-91)	73 (38-84)	0.7438
Sex			0.4262			0.2751
Male	24 (46.1)	40 (53.3)		19 (45.2)	24 (57.1)
Female	28 (53.8)	35 (46.6)		23 (54.7)	18 (42.8)
BMI (kg/m2)	22.2 (17.7-28.3)	22.8 (16.7-38.6)	0.5964	22.3 (17.7-28.3)	23.0 (16.7-30.2)	0.8829
ASA-PS			0.2370			0.2808
I	4 (7.6)	7 (9.3)		2 (4.7)	5 (11.9)
II	42 (80.7)	51 (68.0)		35 (83.3)	29 (69.0)
III	6 (11.5)	17 (22.6)		5 (11.9)	8 (19.0)
CCI			0.0703			0.2640
Low/medium	35 (67.3)	38 (50.6)		28 (66.6)	23 (54.7)
High	17 (32.6)	37 (49.3)		14 (33.3)	19 (45.2)
Previous abdominal operation			0.8833			0.8114
Yes	16 (30.7)	24 (32.0)		13 (30.9)	12 (28.5)
No	36 (69.2)	51 (68.0)		29 (69.0)	30 (71.4)
CEA (ng/mL)	3 (0.9-29.1)	3.5 (0.9-89.8)	0.1426	3.2 (1.0-29.1)	3.5 (0.9-42.1)	0.7807
Bowel preparation			0.7705			0.4154
MBP	21 (40.3)	35 (46.6)		17 (40.4)	23 (54.7)
OABP	29 (55.7)	37 (49.3)		24 (57.1)	18 (42.8)
None	2 (3.8)	3 (4.0)		1 (2.3)	1 (2.3)
Surgical procedure			0.0249			0.8546
Ileocecal resection	19 (36.5)	33 (44.0)		19 (45.2)	16 (38.1)
Right hemicolectomy	12 (23.0)	21 (28.0)		12 (28.5)	15 (35.7)
Left hemicolectomy	7 (13.4)	0 (0)		0 (0)	0 (0)
Sigmoidectomy	4 (7.6)	8 (10.6)		4 (9.5)	5 (11.9)
Partial resection	10 (19.2)	13 (17.3)		7 (16.6)	6 (14.2)
Lymph node dissection area			0.0133			1.0000
D2	2 (3.8)	14 (18.6)		1 (2.3)	1 (2.3)
D3	50 (96.1)	61 (81.3)		41 (97.6)	43 (97.6)
Tumor location			0.1940			0.7757
Right-sided	38 (73.0)	62 (82.6)		34 (80.9)	35 (83.3)
Left-sided	14 (26.9)	13 (17.3)		8 (19.0)	7 (16.6)
Tumor diameter (mm)	31 (0-80)	32 (0-110)	0.1722	33 (0-80)	30 (0-90)	0.9928
Differentiation			0.6351			0.9745
G1	28 (53.8)	38 (50.6)		24 (57.1)	23 (54.7)
G2	22 (42.3)	31 (41.3)		16 (38.1)	17 (40.4)
G3	2 (3.8)	6 (8.0)		2 (4.7)	2 (4.7)
T stage			0.7605			0.8268
T1-2	25 (48.0)	34 (45.3)		20 (47.6)	19 (45.2)
T3-4	27 (51.9)	41 (54.6)		23 (52.3)	23 (54.7)
N stage			0.4624			0.4834
N+	17 (32.6)	20 (26.6)		12 (28.5)	15 (35.7)
N0	35 (67.3)	55 (73.3)		30 (71.4)	27 (64.2)
Lymphatic invasion			0.3614			0.2512
Yes	32 (61.5)	52 (69.3)		25 (59.5)	30 (71.4)
No	20 (38.4)	23 (30.6)		17 (40.4)	12 (28.5)
Venous invasion			0.9346			0.4740
Yes	17 (32.6)	24 (32.0)		11 (26.2)	14 (33.3)
No	35 (67.3)	51 (68.0)		31 (73.8)	28 (66.6)
Perineural invasion			0.8157			0.3927
Yes	12 (23.0)	16 (21.3)		9 (21.4)	6 (14.2)
No	40 (76.9)	59 (78.6)		33 (78.5)	36 (85.7)
TNM stage			0.7146			0.8696
0	3 (5.7)	7 (9.3)		3 (7.1)	2 (4.7)
I	18 (34.6)	25 (33.3)		15 (35.7)	15 (35.7)
II	14 (26.9)	24 (32.0)		12 (28.5)	10 (23.8)
III	17 (32.6)	19 (25.3)		12 (28.5)	15 (35.7)

IA: Intracorporeal anastomosis; EA: Extracorporeal anastomosis; BMI: Body mass index; ASA-PS: American Society of Anesthesiologists physical status; CCI: Charlson comorbidity index; MBP: Mechanical bowel preparation; OABP: Oral antibiotic bowel preparation; CEA: Carcinoembryonic antigen.